mCRPC: Survival with enzalutamide and abiraterone improved in Blacks vs Whites

Key clinical point: A significant improvement in overall survival is seen in chemotherapy-naïve Black vs White patients with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone or enzalutamide.

Major finding: The median follow-up was 19.0 and 18.7 months in Black and White patients, respectively. The overall survival was significantly longer in Black vs White patients (hazard ratio, 0.67; P <.0001).

Study details: A retrospective study of 2,910 patients with mCRPC from the Veterans Health Administration database who received enzalutamide or abiraterone after castration between April 2014 and March 2017.

,

Disclosures: This study was sponsored by Pfizer Inc. and Astellas Pharma, Inc. The authors received grants, personal/consulting fees, and nonfinancial support outside this work. Some authors were being employed and/or held stocks in various pharmaceutical companies.

Source: George DJ et al. Prostate Cancer Prostatic Dis. 2021 Nov 3. doi: 10.1038/s41391-021-00463-9.